The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ADMA BIOLOGICS INC | COM | 000899104 | 2,139,097 | 597,513 | SH | SOLE | 597,513 | 0 | 0 | |||
| AGIOS PHARMACEUTICALS INC | COM | 00847X104 | 119,617 | 4,833 | SH | SOLE | 4,833 | 0 | 0 | |||
| ALIMERA SCIENCES INC | COM NEW | 016259202 | 52,188,977 | 16,835,154 | SH | SOLE | 16,835,154 | 0 | 0 | |||
| ANIKA THERAPEUTICS INC | COM | 035255108 | 20,145,737 | 1,081,360 | SH | SOLE | 1,081,360 | 0 | 0 | |||
| EVOLUS INC | COM | 30052C107 | 15,390,261 | 1,683,836 | SH | SOLE | 1,683,836 | 0 | 0 | |||
| EXELIXIS INC | COM | 30161Q104 | 19,899,451 | 910,730 | SH | SOLE | 910,730 | 0 | 0 | |||
| INTERCEPT PHARMACEUTICALS INC | PUT | 45845P958 | 22,248,000 | 1,200,000 | SH | Put | SOLE | 1,200,000 | 0 | 0 | ||
| LIQUIDIA CORP | COM NEW | 53635D202 | 58,604,595 | 9,243,627 | SH | SOLE | 9,243,627 | 0 | 0 | |||
| SOCIETAL CDMO INC | COM | 75629F109 | 794,191 | 1,689,768 | SH | SOLE | 1,689,768 | 0 | 0 | |||
| STANDARD BIOTOOLS INC | COM | 34385P108 | 22,104,998 | 7,622,413 | SH | SOLE | 7,622,413 | 0 | 0 | |||
| VERONA PHARMA PLC | SPONSORED ADS | 925050106 | 2,983,943 | 183,064 | SH | SOLE | 183,064 | 0 | 0 | |||
| VERRICA PHARMACEUTICALS INC | COM | 92511W108 | 1,009,817 | 259,593 | SH | SOLE | 259,593 | 0 | 0 | |||
| Y-MABS THERAPEUTICS INC | COM | 984241109 | 127,099 | 23,321 | SH | SOLE | 23,321 | 0 | 0 | |||